Volume 17.07 | Feb 22

Issue 17.07 February 22, 2016
Cell Therapy News - Your Industry in an Instant
Your Industry in an Instant Twitter   Facebook  
Publications | Reviews | Science | Policy | Business | NIH | CBER | Regulatory | Events | Jobs
 
TOP STORY
Engineered Mini-Stomachs Produce Insulin in Mice
Researchers have discovered that tissue from the lower stomach has the greatest potential to be reprogrammed into a beta-cell state. They took samples of this tissue from mice and grew them into “mini-organs” that produced insulin when transplanted back into the animals. [Press release from Cell Press (EurekAlert!) discussing online publication in Cell Stem Cell] Press Release | Full Article | Graphical Abstract
Download Mini-Review: Myogenic Progenitor and Satellite Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
Cell Therapy Centered on IL-1Ra Is Neuroprotective in Experimental Stroke
Investigators asked if cell-based delivery of the interleukin-1 receptor antagonist (IL-1Ra), a known neuroprotectant in stroke, can promote neuroprotection, by modulating the detrimental inflammatory response in the tissue at risk. [Acta Neuropathol] Full Article

Cell-Free Multi-Layered Collagen-Based Scaffolds Demonstrate Layer Specific Regeneration of Functional Osteochondral Tissue in Caprine Joints
The long term ability of a multi-layered biomimetic collagen-based scaffold to repair osteochondral defects was investigated in a large animal model: namely critical sized lateral trochlear ridge and medial femoral condyle defects in the caprine stifle joint. [Biomaterials] Abstract

Autonomous Extracellular Matrix Remodeling Controls a Progressive Adaptation in Muscle Stem Cell Regenerative Capacity during Development
Investigators showed that fetal muscle stem cells (MuSCs) resist progenitor specification and exhibit altered division dynamics, intrinsic features that are progressively lost postnatally. After transplantation, fetal MuSCs expanded more efficiently and contributed to muscle repair. [Cell Rep]
Full Article | Graphical Abstract | Press Release

Serially Transplanted Non-Pericytic CD146 Adipose Stromal/Stem Cells in Silk Bioscaffolds Regenerate Adipose Tissue In Vivo
Scientists hypothesized that an adipose progenitor could be sorted based on the expression of CD146, CD34, and/or CD29 and when implanted in vivo these cells can persist, proliferate, and re-generate a functional fat pad over serial transplants. [Stem Cells] Abstract

Human Salivary Gland Stem Cells Functionally Restore Radiation Damaged Salivary Glands
Investigators showed the isolation of adult human salivary gland stem/progenitor cells and demonstrate at the single cell level in vitro self-renewal and differentiation into multilineage organoids. They also showed in vivo functionality, long-term engraftment and functional restoration in a xenotransplantation model. [Stem Cells] Abstract

Poly(Limonene Thioether) Scaffold for Tissue Engineering
A photocurable thiol-ene network polymer, poly(limonene thioether), was synthesized, characterized, fabricated into tissue engineering scaffolds, and demonstrated in vitro and in vivo. [Adv Healthc Mater] Abstract

Suicide Gene-Engineered Stromal Cells Reveal a Dynamic Regulation of Cancer Metastasis
Investigators developed an engineered human cancer-associated fibroblast (CAF) cell line with an inducible suicide gene to enable selective in vivo elimination of human CAFs at different stages of xenograft tumor development, effectively circumventing the challenge of targeting a cell-specific marker. [Sci Rep] Full Article | Press Release

In Vivo Evaluation of a Simvastatin-Loaded Nanostructured Lipid Carrier for Bone Tissue Regeneration
Simvastatin-loaded nanostructured lipid carriers (SNs) were fabricated and the osteogenic effect of the SNs was evaluated in a critical-sized rabbit calvarial defect. Results revealed that the SNs significantly enhanced bone formation in vivo, as evaluated by hematoxylin and eosin staining, immunohistochemistry, and a fluorescence analysis. [Nanotechnology] Full Article

Design and Characterization of the Tumor Vaccine MGN1601, Allogeneic Fourfold Gene-Modified Vaccine Cells Combined with a TLR-9 Agonist
The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma. Use of the vaccine in a therapeutic setting showed complete response in 92% of mice as well as synergistic action and necessity of the components. [Mol Ther Oncolytics] Full Article

Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
 
REVIEWS
Muse Cells Provide the Pluripotency of Mesenchymal Stem Cells: Direct Contribution of Muse Cells to Tissue Regeneration
The author details the unique characteristics of multilineage-differentiating stress enduring (Muse) cells and describes their future application for regenerative medicine. [Cell Transplant] Full Article

Stem Cell Transplantation for the Treatment of Immunodeficiency in Children: Current Status and Hopes for the Future
Investigators describe current strategies employed to improve outcomes in primary immunodeficiencies, focusing on new developments in hematopoietic stem cell transplantation, gene and cell therapy. [Expert Rev Clin Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research fields.

Request your Free Wallchart on Naive and Primed Stem Cell States
 
SCIENCE NEWS
More Evidence of the Power of Mesenchymal Stem Cell Transplant to Block Opioid-Induced Hyperalgesia and Tolerance
Cleveland Clinic researchers have found new evidence that modulating neuroinflammation with stem cell transplants may prove to be an effective strategy to treat both opioid tolerance and opioid-induced hyperalgesia. [Press release from the American Academy of Pain Medicine (AAPM) discussing research presented at the 32nd AAPM Annual Meeting, Palm Springs] Press Release

Enter to WIN a Free Pass to Cell Culture World Congress USA 2016!
 
POLICY
Peer Review System for Awarding NIH Grants Is Flawed
The mechanism used by the National Institutes of Health (NIH) to allocate government research funds to scientists whose grants receive its top scores works essentially no better than distributing those dollars at random, new research suggests. [Johns Hopkins Bloomberg School of Public Health] Press Release | Report

US Cancer Institute to Overhaul Tumor Cell Lines
After more than 25 years of heavy use by researchers around the world, the US National Cancer Institute (NCI) has decided to retire the NCI-60, its panel of 60 human cancer cell lines grown in culture. The institute will launch a rejuvenated repository of cancer models that are derived from fresh patient samples and tagged with details about their clinical past. [Nature News] Editorial

NIH to Review Its Policies on All Nonhuman Primate Research
The National Institutes of Health (NIH) is about to take a closer look at the use of nonhuman primates in all federally funded U.S. research labs. In response to a congressional mandate, the agency will convene a workshop this summer to review the ethical policies and procedures surrounding work on monkeys, baboons, and related animals. [ScienceInsider] Editorial

For RNA Paper Based on a Computer Game, Authorship Creates an Identity Crisis
A journal published a paper that reveals a set of folding constraints in the design of RNA molecules. Most of the data for the study come from an online game that crowdsources solutions from thousands of nonexpert players. But the lead authors of the paper are the players themselves. And there’s a twist: The journal nearly delayed publication because of “ethical” concerns about authors using only their game names. [ScienceInsider] Editorial

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
 
BUSINESS
Cutting Edge Medical Research Ideas Receive £23.2 Million Boost
The Medical Research Council is accelerating innovative medical research with £23.2 million in new funding to take ground-breaking ideas from UK universities into industry and out to patients. [Medical Research Council] Press Release

Government of Canada Invests in Research Commercialization
The Centre for Commercialization of Cancer Immunotherapy will receive funding of $15 million over five years to develop, translate and commercialize cancer immunotherapy. [Networks of Centres of Excellence of Canada] Press Release

CIRM Invests in Treatment Focused on High Risk Blood Cancers, Leukemia and Lymphoma
Cord blood transplants can be life saving for people battling deadly blood cancers, but they can also cause complications that are life-threatening. That’s why the California Institute for Regenerative Medicine (CIRM) has approved almost $3.5 million to fund a program to find a more effective, efficient and safer way to deliver those transplants. [California Institute for Regenerative Medicine] Press Release

UTA Researcher Earns NSF CAREER Grant to Develop Conductive Bioelastomers for More Effective, Safer Tissue Engineering
Yi Hong, an assistant professor of bioengineering, has won a five-year, $500,000 National Science Foundation (NSF) Early Career Development, or CAREER, Program grant to create conductive, single-component and biodegradable elastomers. [The University of Texas at Arlington] Press Release

Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children
Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. [Cancer MoonShot 2020] Press Release

AVROBIO Inc. Launches to Develop Novel, Clinical-Stage Cell and Gene Therapies Targeting Immuno-Oncology and Rare Diseases
AVROBIO announced its launch plans to accelerate development of two novel cell and gene therapies. Phase I programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia and Fabry disease. [AVROBIO Inc.] Press Release

ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program
ImmunoCellular Therapeutics, Ltd. announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell receptors developed in the laboratory of Prof. Mark Davis at Stanford University School of Medicine. [ImmunoCellular Therapeutics, Ltd.] Press Release

BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents
Asterias Biotherapeutics, Inc. and BioTime, Inc. and BioTime’s wholly owned subsidiary ES Cell International Pte Ltd, have entered into a Share Transfer Agreement through which BioTime will re-acquire from Asterias shares of capital stock of BioTime subsidiaries Cell Cure Neurosciences Ltd and OrthoCyte Corporation. [BioTime, Inc.] Press Release

Gene Therapy for Parkinson’s Disease to Be Tested by Pitt, UPMC Experts
Experts at the University of Pittsburgh School of Medicine are leading the second arm of a clinical trial using gene therapy to relieve the symptoms of tremor and mobility impairment in patients with Parkinson’s disease. [University of Pittsburgh School of Medicine] Press Release

Medigene Secures Additional Viral Vector Production Capacities for Its Clinical TCR Studies
Medigene AG has signed an agreement with the contract manufacturer EUFETS GmbH for the production and delivery of viral vectors. These viral vectors are required for Medigene’s upcoming clinical T-cell receptor (TCR) studies. [Medigene AG] Press Release
 
NIH
National Institute of General Medical Sciences; Notice of Closed Meetings (FR Doc. No: 2016-03414)

Center For Scientific Review; Notice of Closed Meetings (FR Doc. No: 2016-03416)
 
CBER
Determining the Extent of Safety Data Collection Needed in Late-Stage Premarket and Postapproval Clinical Investigations; Guidance for Industry; Availability

Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus; Guidance for Industry; Availability
 
REGULATORY
Food and Drug Administration (United States)

Removal of Review and Reclassification Procedures for Biological Products Licensed Prior to July 1, 1972 (FR Doc. No: 2016-02884)
 
EVENTS
NEW AACR Annual Meeting 2016
April 16-20, 2016
New Orleans, United States

Visit our events page to see a complete list of events in the cell, gene and immunotherapy community.
 
JOB OPPORTUNITIES
NEW PhD Positions – Cancer, Microbiology and Stem Cell Engineering (Virginia Commonwealth University)

NEW PhD Positions – Tendon Repair and Regeneration (NUI Galway)

Lead Scientist – Translational Therapy (NHS Blood and Transplant)

PhD Position – Leukemogenesis and Treatment Resistance (Institute for Tumor Biology and Experimental Therapy)

Postdoctoral Positions – Gene Regulation and Translational Cancer Research (University of Texas Health Science Center)

Postdoctoral Position – Hematology/Oncology (Penn State College of Medicine)

Director of Manufacturing – Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow/Research Associate – Cancer Therapy (Memorial Sloan Kettering Cancer Center)

Translational Research Scientist – Hematology/Oncology (University of Chicago)

Staff Scientist – Cell Therapy Process Development (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.